



SHORTENED CURRICULUM VITAE (last 6 years) STANDARDIZED SHEET

Date: 12th June 2024

A. PERSONAL DATA

First and Family name	GUADALUPE RIVERO		
Researcher numbers	Researcher ID	U-3843-2019	
	Orcid code	0000-0002-2537-4047	

A.1. Current professional situation

Name of University/Institution	University of the Basque Country				
Faculty/School/Institute	Medicine and Nursery				
Dpt./Centre	Pharmacology				
Address and Country	Sarriena auzoa z/g, Leioa 48940 Spain				
Phone number	+34 946013493	E-mail	guadalupe.rivero@ehu.eus		
Professional category	Associate professor (Profesora agregada)			Start date	24/02/2022
Current position	Permanent staff	X	Tenured-track	Acting official	
	Grantee		Other (specify)		
Type of contract	Full-time		X	Part-time	
UNESCO spec. code	320909				
Keywords	Neurotransmitters, neurotransmitter receptors, GPCR, molecular mechanisms of disease, Neuropsychopharmacology, Psychopharmacology, post-mortem human brain, psychiatric diseases				

A.2. Academic education

Bachelor/Master/PhD	Degree awarding entity	Year
Bsc in Pharmacy	UPV/EHU	2002
PhD in Pharmacy	UPV/EHU	2008

A.3. Previous positions and activities

Professional category	Employing entity	Dates
Predoctoral researcher	UPV/EHU	2002-2008
Postdoctoral researcher	University of Bristol	2008-2011
Researcher	Omnia Molecular	2011-2012
Project manager	Institute for Bioengineering of Catalonia	2013
Postdoctoral researcher	UPV/EHU	2013-2015
Assistant professor (Profesora adjunta)	UPV/EHU	2016-2022

A.4. General quality indicators of scientific production

Indicate the values for your whole scientific career

N. of six-year terms positively evaluated (in Spain)	2
Date of the last six-year term awarded	31/12/2018
N. of PhD thesis supervised	1+1 ongoing
H index (Web of Science, if not indicate source)	11
N. of papers in Q1 (Web of Science)	13
Total number of publications	23
Total number of indexed publications	16
Total number of citations	497 by 427 documents
Average of citations per year	29.2
Other indicators of your research activity (specify)	

B. SUMMARY OF THE CURRICULUM (3500 characters at most, including spaces)

Please, briefly describe your scientific career, your main scientific-technical achievements, your scientific-technical interests and goals in the medium/long-term for your research lines. Indicate also other aspects or specific features that you may find relevant to understand your career.

Over my 20-year research career, I have investigated psychiatric disorders from a translational perspective with the aim of finding more effective and safer pharmacological treatments. I have mainly used postmortem human brain (PHB) as well as animal and cellular systems.

I did my Doctoral Thesis in the Dept of Pharmacology (UPV/EHU) under the supervision of Drs Javier Meana and Ane Gabilondo. We found enhanced agonist radioligand-labeled α_2 -adrenoceptor density in PHB of subjects with major depression, which could relate to the lack of antidepressant treatment efficacy in these patients. Possible mechanisms were evaluated biochemically and genetically and compared to own results in other psychiatric disorders. This work led to 8 articles in first and second quartile journals. Four of these articles were collaborative studies with Dr García-Sevilla (University of Balearic Islands) and Dr García-Orad (UPV/EHU). Thanks to a third research stay in the University of Bristol (UoB), the Thesis gained *Doctor Europeus* mention.

In 2008-2011 years, I was a postdoctoral researcher in Drs Eamonn Kelly and Graeme Henderson's lab (Dept of Physiology and Pharmacology, UoB). We studied functional selectivity at μ -opioid receptor with a focus on morphine tolerance. Two of the 4 published articles have been specially relevant with 218 and 87 cites since 2010 and 2012, respectively. Briefly, we found endomorphin-2 to be a biased agonist towards arrestin3 pathway which would relate to enhanced μ -opioid receptor desensitization and internalization.

In 2011-2012 years, I was a researcher in biotech company Omnia Molecular (OM). OM's aim was to find new anti-infectives through the inhibition of pathogenic tRNA synthases. I performed research tasks in European projects using proprietary technology and microbiological assays. Along with my work at OM and as Project Manager in the Institute for Bioengineering of Catalonia (year 2013), I have gained experience at management and business development. Notably, at OM I was Principal Investigator of grant proposals awarded by European Commission's 7th Framework Programme.

Back in the UPV/EHU as researcher (2013-2015) and as Assistant Professor (2016-2022), I joined Dr Javier Meana led Neuropsychopharmacology group. I perform epigenetic and transcriptional studies in PHB of subjects with psychiatric disorders. Transcriptional studies are performed in collaboration with Biobizkaia Health Research Institute and with Sergi Mas (IDIBAPS, University of Barcelona) and Raul Andero's lab (Autonomous University of Barcelona). The recently started research line in epigenetics has led to two works in *Translational psychiatry* and *Journal of Psychiatry and Neuroscience*, in which I have participated as corresponding author.

Over the years, I have earned 6 competitive grants and I have participated in 23 research projects, 4 being European collaborative projects, and 3 research networks, from which CIBERSAM is highlighted. I am currently the principal investigator of one of the subprojects in a coordinated project funded by *Fundació La Marató de TV3*.

Regarding undergraduate and graduate training, I have been lecturer in Pharmacy, Physiotherapy and Medicine Degree as well as in 3 Master degrees. I have supervised four Master's and 12 Final Year Dissertations. Together with Dr Alfredo Ramos-Miguel I have supervised one Doctoral Thesis which was defended in May 2024 and we are now supervising a second year PhD student.

C. MOST RELEVANT MERITS

Please indicate merits corresponding only to the last 6 years. In the event of an interruption in the investigative work motivated by any of the situations foreseen in the second paragraph of point 13 of article 26 of the announcement Order, the period of investigative activity to be taken into account may be increased as established in that paragraph.

C.1. Indexed publications

Authors: Diez-Alarcia R., Muguruza C., Rivero G., García-Bea A., Gómez-Vallejo V., Callado L.F., Llop J., Martín A., Meana J.J.

Title: Opposite alterations of 5-HT_{2A} receptor brain density in subjects with schizophrenia: relevance of radiotracers pharmacological profile.

Name of journal: Translational Psychiatry

Volume: 11 Initial pag: 302 Final pag: 302 Year: 2021

ISSN: 2158-3188 Publication place: Online

Quality indicators: Data base: Journal Citation Reports: Impact factor 2021 (year of publication): 7.989
Quartile: 1 (*Psychiatry*)

Authors: Brocos-Mosquera I., Miranda-Azpiazu P., Muguruza C., Corzo-Monje V., Morentin B., Meana J.J., Callado L.F., Rivero G.

Title: Differential brain ADRA_{2A} and ADRA_{2C} gene expression and epigenetic regulation in schizophrenia. Effect of antipsychotic drug treatment.

Name of journal: Translational Psychiatry

Volume: 11 Initial pag: 643 Final pag: 643 Year: 2021

ISSN: 2158-3188 Publication place: Online

Quality indicators: Data base: Journal Citation Reports: Impact factor 2021 (year of publication): 7.989
Quartile: 1 (*Psychiatry*)

Authors: Martínez-Peula O., Morentin B., Callado L.F., Meana J.J., Rivero G., Ramos-Miguel A.

Title: Permissive epigenetic regulatory mechanisms at the histone level are enhanced in postmortem dorsolateral prefrontal cortex of individuals with schizophrenia

Name of journal: Journal of Psychiatry and Neuroscience

Volume: 49 Initial pag: E35 Final pag: E44 Year: 2024

ISSN: 1180-4882 Publication place: Online

Quality indicators: Data base: Journal Citation Reports: Impact factor 2022: 4.3
Quartile: 2 (*Psychiatry*)

Authors: DelaCuesta-Barrutia J., Martínez-Peula O., Rivero G., Santas-Martín J.A., Munarriz-Cuezva E., Brocos-Mosquera I., Miranda-Azpiazu P., Diez-Alarcia R., Morentin B., Honer W.G., Callado L.F., Erdozain A.M., Ramos-Miguel A.

Title: Effect of antipsychotic drugs on group II metabotropic glutamate receptor expression and epigenetic control in postmortem brains of schizophrenia subjects

Name of journal: Translational Psychiatry

Volume: 14 Initial pag: 113 Final pag: 113 Year: 2024

ISSN: 2158-3188 Publication place: Online

Quality indicators: Data base: Journal Citation Reports: Impact factor 2022 (year of publication): 6.8
Quartile: 1 (*Psychiatry*)

C.2. Other publications

KEY: B= book, BC= book chapter, P= scientific paper, R= review, E= editor, S= scientific-technical document, O= other (specify).

Authors: Erdozain A., Miguélez C., Rivero G.

Title: Aspectos generales de Farmacovigilancia

Name of journal/Title of book: Curso OpenCourseWare de UPV/EHU.

Key: O (Online learning resources)

Volume: N/A

Initial pag: N/A

Final pag: N/A

Year: 2017

Publisher (for books):

Publication place:

Online.

ISSN: 2255-2316

Quality indicators: N/A

Authors: Erdozain A., Miguélez C., Rivero G.

Title: Farmakojagoletzaren orokortasunak

Name of journal/Title of book: Curso OpenCourseWare de UPV/EHU.

Key: O (Online learning resources)

Volume: N/A

Initial pag: N/A

Final pag: N/A

Year: 2018

Publisher (for books):

Publication place:

Online.

ISSN: 2255-2316

Quality indicators: N/A

Authors: Martínez-Peula O., Rivero G.

Title: Epigenetika helburu duten sendagaiak

Name of journal/Title of book: Ekaia (Revista de Ciencia y Tecnología de la UPV/EHU publicada en euskera)

Key: R

Volume: 40

Initial pag: 11

Final pag: 31

Year: 2021

Publisher (for books):

Publication place:

Online. ISBN/ISSN: 214-9001

Quality indicators: N/A

Authors: Mendiguren A., Rivero G., Baltziskueta E., Pineda J.

Title: Principios farmacológicos y clínicos de la prescripción racional de medicamentos

Name of journal/Title of book: Principios farmacológicos y clínicos de la prescripción racional de medicamentos

Key: B

Volume: N/A

Initial pag: N/A

Final pag: N/A

Year: 2023

Publisher (for books): UPV/EHU

Publication place:

ISBN 9788413195889

Quality indicators: N/A

C.3. Works submitted to national or international conferences and seminars

Indicate a maximum of 10 contributions

Authors: Rivero G., Brocos-Mosquera I., Meana J.J., Callado L.F.

Title: ADRA2A gene expression and epigenetic regulation in postmortem prefrontal cortex of subjects with schizophrenia

Type of contribution: Talk. Special mention.

Conference: XXXVIII Congreso de la Sociedad Española de Farmacología. 1st Meeting in Translational Pharmacology.

Publication: Basic and Clinical Pharmacology and Toxicology 123 (Suppl. 2) p62-63.

City of event: Santiago de Compostela

Date: June 2018

Authors: Rivero G., Muguruza C., Corzo V., Meana J.J., Callado L.F.

Title: ADRA2A and ADRA2C gene expression in post-mortem brain is differentially upregulated in subjects with major depressive disorder and schizophrenia

Type of contribution: Poster

Conference: 31st European College of Neuropsychopharmacology Congress 2018

Publication: European Neuropsychopharmacology, Volume 29, Supplement 1, 2019, Pages S40-S41.

City of event: Barcelona

Date: October 2018

Authors: Díez-Alarcia R., Muguruza C., Rivero G., García-Bea A., Callado L.F., Martín A., Llop J., Meana J.J.

Title: Human cerebral 5-HT_{2A} receptor labelling with [¹⁸F]altanserin, [³H]LSD, and [³H]M100907.

Relevance of radiotracer intrinsic activity

Type of contribution: Poster

Conference: 31st European College of Neuropsychopharmacology Congress 2018

Publication: European Neuropsychopharmacology, Volume 29, Supplement 1, 2019, Page S324.

City of event: Barcelona

Date: October 2018

Authors: Martínez-Peula O., Rivero G., Morentin B., Callado L.F., Meana J.J. and Ramos-Miguel A.

Title: Histone H3 and H4 posttranslational regulation in schizophrenia postmortem brain: Effect of antipsychotic treatment

Type of contribution: Poster

Conference: 2020 Congress of the Schizophrenia International Research Society

Publication: Schizophrenia bulletin, Volume 46, Supplement 1, 2020, Page S107

City of event: Online

Date: May 2020

Authors: Martínez-Peula O., Rivero G., Díaz-Grijuela E., Munarriz-Cuezva E., Erdozain A.M., Meana J.J., Ramos-Miguel A.

Title: Selective downregulation of cortical mGlu₂ receptors in the maternal immune activation model of schizophrenia: association with histone posttranslational modifications

Type of contribution: Poster

Conference: 34th European College of Neuropsychopharmacology Congress 2021.

Publication: European Neuropsychopharmacology, Volume 53, Pages S214–S215.

City of event: Lisbon

Date: October 2021

Authors: Martínez-Peula O., Rivero G., Munarriz-Cuezva E., DelaCuesta-Barrutia J., González-Maeso J., Erdozain A.M., Meana J. J., Ramos-Miguel A.

Title: Maternal immune activation and mGlu₂ deficiency: A two-hit model mimicking cognitive impairment in schizophrenia

Type of contribution: Poster

Conference: 2022 Congress of the Schizophrenia International Research Society.

Publication: Abstract book.

City of event: Florence

Date: April 2021

Authors: Martínez-Peula O., Rivero G., Munarriz-Cuezva E., Delacuesta-Barrutia J., Gonzalez-Maeso J., Erdozain A.M., Meana J.J., Ramos-Miguel A.

Title: A two-hit murine model combining MIA and mGlu₂ deficiency: behavioural evaluation and sex differences.

Type of contribution: Poster

Conference: 2023 11th IBRO World Congress of Neuroscience.

Publication: Abstract book.

City of event: Granada

Date: September 2023

Authors: Erkizia-Santamaría I., Rivero G., Horrillo I., Meana J.J., Ortega J.E.
Title: Psilocybin rescues depressive phenotype and modulates serotonin-2A and glucocorticoid receptor mRNA expression in brain cortex of a stress animal model
Type of contribution: Poster
Conference: 2023 36th European College of Neuropsychopharmacology Congress
Publication: Neuroscience Applied, Volume 2 (2023): 102441-102452.
City of event: Barcelona Date: October 2023

Authors: Martínez-Peula O., Ramos-Miguel A., Morentin B., Griñán-Ferré C., Callado L.F., Meana J., Rivero G.
Title: Reduced class I histone deacetylase activity in post-mortem prefrontal cortex of schizophrenia subjects
Type of contribution: Poster
Conference: 2023 36th European College of Neuropsychopharmacology Congress
Publication: Neuroscience Applied, Volume 2 (2023): 102441-102519.
City of event: Barcelona Date: October 2023

Authors: Santas J., Martínez-Peula O., DelaCuesta-Barrutia J., Erdozain A.M., Morentin B., González-Maeso J., Callado L.F., Meana J.J., Ramos-Miguel A., Rivero G.
Title: Metabotropic glutamate receptors immunodensities in schizophrenia subjects brain and in a two-hit mouse model of schizophrenia
Type of contribution: Poster
Conference: 2024 Congress of the Schizophrenia International Research Society.
Publication: Abstract book T222.
City of event: Florence Date: April 2024

C.4. R&D projects funded through competitive calls

Title of the project: Grupo de investigación en Neuropsicofarmacología de la UPV/EHU, Grupo 16 incluido en el CIBER-SAM (Centro de Investigación Biomédica en Red de Salud Mental)
Funding entity (call): Instituto de Salud Carlos III.
Amount awarded: €1,048,151.00
Start date (dd/mm/yy): 01/01/2008 End date (dd/mm/yy): on-going (reviewed in 3 year-cycles)

Principal investigator: J. Javier Meana (UPV/EHU)
Principal investigator: Guadalupe Rivero (UPV/EHU)

Title of the project: Alteraciones del sistema noradrenérgico en los déficits cognitivos de la esquizofrenia: localización, mecanismos y reversión farmacológica
Funding entity (call): Convocatoria del Programa Estatal de Investigación, Desarrollo e Innovación orientada a los retos de la Sociedad (Ministerio de Economía y Competitividad) (2013).
Amount awarded: €130,000
Start date (dd/mm/yy): 01/01/2014 End date (dd/mm/yy): 31/12/2016
Principal investigator: Luis F. Callado (UPV/EHU)

Title of the project: Grupo consolidado Neuropsicofarmacología IT1211-19
Funding entity (call): Grupos consolidados de Investigación del sistema universitario vasco. Gobierno Vasco (2018).
Amount awarded: €301,100
Start date (dd/mm/yy): 01/01/2019 End date (dd/mm/yy): 31/12/2021
Principal investigator: J. Javier Meana (UPV/EHU)

Title of the project: Creación de infraestructura: "Lector multimodal de placas"

Funding entity (call): Ayudas para financiación de la adquisición y renovación de infraestructura científica y fondos bibliográficos en la UPV/EHU (2020).

Amount awarded: €18,682

Start date (dd/mm/yy): 01/01/2020

End date (dd/mm/yy): 31/12/2020

Principal investigator: J. Javier Meana (UPV/EHU)

Title of the project: Estudio de genómica funcional convergente de la esquizofrenia resistente a tratamiento

Funding entity (call): Proyectos de investigación en salud. AES 2020. Instituto de Salud Carlos III. Ministerio de Ciencia e Innovación.

Amount awarded: €86,515

Start date (dd/mm/yy): 01/01/2020

End date (dd/mm/yy): 31/12/2023

Principal investigator: Sergi Mas (University of Barcelona)

Title of the project: Evaluación del efecto antidepresivo del agonista de los receptores 5-HT_{2A} psilocibina en un modelo animal de depresión

Funding entity (call): Fundación Vital (2021).

Amount awarded: €4,400

Start date (dd/mm/yy): 01/01/2022

End date (dd/mm/yy): 31/12/2022

Principal investigator: Jorge Ortega and Guadalupe Rivero (UPV/EHU)

Title of the project: Grupo consolidado Neuropsicofarmacología IT1512-22

Funding entity (call): Grupos consolidados de Investigación del sistema universitario vasco. Gobierno Vasco (2021).

Amount awarded: €502,425

Start date (dd/mm/yy): 01/01/2022

End date (dd/mm/yy): 31/12/2025

Principal investigator: Luis F. Callado (UPV/EHU)

Title of the project: Brain and blood coexpression networks using DDR1 as a seed gene in bipolar disorder

Funding entity (call): Fundació La Marató TV3 (2022).

Amount awarded: €399.606,25. At UPV/EHU: €106.531,25

Start date (dd/mm/yy): 01/04/2023

End date (dd/mm/yy): 30/03/2025

Principal investigator: Guadalupe Rivero (UPV/EHU) and coordinator: Elisabet Vilella (IISPV)

Title of the project: Type II metabotropic glutamate receptors in schizophrenia: Role in neurodevelopment and their utility as biomarkers of the illness

Funding entity (call): Proyectos de Generación de Conocimiento» Formato Memoria Científico-Técnica Proyectos Individuales (Ministerio de Ciencia e Innovación) (2022)

Amount awarded: €203.166,00

Start date (dd/mm/yy): 01/01/2023

End date (dd/mm/yy): 31/12/2026

Principal investigator: Alfredo Ramos (UPV/EHU)

Title of the project: Identificación de nuevos biomarcadores plasmáticos asociados a depresión. Validación preclínica de su respuesta a nuevas estrategias terapéuticas basadas en la administración de esketamina y psilocibina

Funding entity (call): Financiado por Ayudas a Proyectos de Investigación y Desarrollo en Salud. Departamento de Salud del Gobierno Vasco. (2022)

Amount awarded: €125.404,4

Start date (dd/mm/yy): 01/01/2022

End date (dd/mm/yy): 31/12/2025

Principal investigator: Jorge Ortega (UPV/EHU)

Title of the project: Control inhibitorio sobre la propagación de Tau en la enfermedad de Alzheimer

Funding entity (call): Financiado por la Convocatoria de Ayudas a la Investigación en Alzheimer de la Fundación Vasca de Innovación e Investigación Sanitarias (BIOEF). EITB Maratoia (2021)

Amount awarded: €156.376,00

Start date (dd/mm/yy): 01/01/2023

End date (dd/mm/yy): 31/12/2026

Principal investigator: Alfredo Ramos (UPV/EHU)

C.7. Supervision of doctoral thesis

Title: Crosstalk between mGluR2 and epigenetics in schizophrenia: evidence in an animal model and human postmortem brain

PhD student: Oihane Martínez Peula

University: UPV/EHU

Doctorate school: UPV/EHU

Department/PhD program: Pharmacology

Supervisors: Guadalupe Rivero Calera and Alfredo Ramos Miguel

Obtained qualifications: Cum Laude. International Doctorate Special Mention

Year: 2024

Title: Role of metabotropic glutamate receptor 2 in the etiopathology of schizophrenia: functional and pharmacological approach from the mouse model of Maternal Immune Activation.

PhD student: Jon Ander Santas Martín

University: UPV/EHU

Doctorate school: UPV/EHU

Department/PhD program: Pharmacology

Supervisors: Guadalupe Rivero Calera and Alfredo Ramos Miguel

Obtained qualifications: Ongoing

Year: Expected in 2027

C.9. Participation in scientific, technical and/or assessment committees

Committee title: Final year dissertation Board (twice)

Affiliation entity: UPV/EHU (Faculty of Pharmacy)

Scope: Evaluate Final year dissertations presented by students

Type of participation: Chair

Start date (dd/mm/yy): 26/02/2018

End date (dd/mm/yy): 26/06/2018

Committee title: Final year dissertation Board (four times)

Affiliation entity: UPV/EHU (Faculty of Medicine)

Scope: Evaluate Final year dissertations presented by students

Type of participation: Chair

Start date (dd/mm/yy): 01/06/2020

End date (dd/mm/yy): 26/06/2023

Committee title: Master's dissertation Board (four times)

Affiliation entity: UPV/EHU (Faculty of Medicine)

Scope: Evaluate Master's final dissertations presented by students

Type of participation: Chair

Start date (dd/mm/yy): 01/06/2020

End date (dd/mm/yy): 26/06/2022

Committee title: Doctoral thesis dissertation Board

Affiliation entity: University of Barcelona (Faculty of Pharmacy)

Scope: Evaluate Foteini Vasilopoulou's Doctoral Thesis: "Targeting the I2 Imidazoline Receptors: the neuroprotective role of selective ligands in Alzheimer's Disease".

Type of participation: Secretary

Start date (dd/mm/yy): 21/09/2021

End date (dd/mm/yy): 21/09/2021

Committee title: Doctoral thesis dissertation Board

Affiliation entity: University of the Basque Country

Scope: Evaluate Amaia Nuñez's Doctoral Thesis: "Involvement of the matricellular protein hevin in alcohol use disorder: evidence from postmortem human brain and animal models".

Type of participation: Secretary

Start date (dd/mm/yy): 30/01/2023

End date (dd/mm/yy): 30/01/2023

Committee title: Doctoral thesis dissertation Board

Affiliation entity: University of the Basque Country

Scope: Evaluate Irati Rodilla's Doctoral Thesis: "Regulation of electrophysiological effects of opioids by the prostanoid system in the rat locus coeruleus".

Type of participation: Secretary

Start date (dd/mm/yy): 19/07/2023

End date (dd/mm/yy): 19/07/2023

Committee title: Reviewer of scientific publications

Affiliation entity: *Translational Psychiatry* journal

Scope: Peer-review evaluation of scientific papers submitted to the journal (twice)

Type of participation: Reviewer

Start date (dd/mm/yy): 01/07/2016

End date (dd/mm/yy): 17/11/2023

Committee title: Reviewer of scientific publications

Affiliation entity: *Adicciones* journal

Scope: Peer-review evaluation of scientific papers submitted to the journal

Type of participation: Reviewer

Start date (dd/mm/yy): 01/08/2017

End date (dd/mm/yy): 24/10/2017

Committee title: Reviewer of scientific publications submitted to *Ikergazte* congress

Affiliation entity: *Ikergazte* congress

Scope: Evaluation of scientific works submitted to the congress

Type of participation: Reviewer

Start date (dd/mm/yy): 31/03/2021

End date (dd/mm/yy): 31/03/2021

Committee title: Reviewer of scientific publications
Affiliation entity: *Journal of Neuroscience Methods*
Scope: Peer-review evaluation of scientific papers submitted to the journal
Type of participation: Reviewer
Start date (dd/mm/yy): 29/11/2021 End date (dd/mm/yy): 09/01/2022

Committee title: Reviewer of scientific publications
Affiliation entity: *Open Journal of Pharmacology and Pharmacotherapeutics*
Scope: Peer-review evaluation of scientific papers submitted to the journal
Type of participation: Reviewer
Start date (dd/mm/yy): 23/04/2021 End date (dd/mm/yy): 27/04/2021

Committee title: Reviewer of scientific publications
Affiliation entity: *Ekaia*
Scope: Peer-review evaluation of scientific papers submitted to the journal
Type of participation: Reviewer
Start date (dd/mm/yy): 10/11/2022 End date (dd/mm/yy): 10/02/2023

Committee title: Reviewer of scientific publications
Affiliation entity: "*Personalized epigenetics. Second edition*" book edited by Trygve Tollefsbol and published by Elsevier and Academic Press
Scope: Evaluation of the chapter *Personalized epigenetics and neurological disorders*
Type of participation: Reviewer
Start date (dd/mm/yy): 03/10/2023 End date (dd/mm/yy): 03/10/2023

Committee title: Reviewer of scientific publications
Affiliation entity: *Molecular Psychiatry*
Scope: Peer-review evaluation of scientific papers submitted to the journal
Type of participation: Reviewer
Start date (dd/mm/yy): 13/05/2024 End date (dd/mm/yy): 13/05/2024

Committee title: Reviewer of scientific publications
Affiliation entity: *Neuroscience Applied*
Scope: Peer-review evaluation of scientific papers submitted to the journal
Type of participation: Reviewer
Start date (dd/mm/yy): 15/04/2024 End date (dd/mm/yy): 15/04/2024

Committee title: Expert consultant researcher (three times)
Affiliation entity: Elhuyar zientzia azoka (Elhuyar Science Fair)
Scope: Consultancy for middle education centers participating in the Elhuyar Science Fair
Type of participation: Expert consultant researcher
Start date (dd/mm/yy): 01/12/2017 End date (dd/mm/yy): 01/06/2022

Committee title: Evaluation and Supervision of R&D&I Projects
Affiliation entity: Plan Nacional sobre Drogas (Ministerio de Sanidad)
Scope: Review of R&D project proposals
Type of participation: Expert consultant researcher
Start date (dd/mm/yy): 01/08/2023 End date (dd/mm/yy): 15/09/2023

Committee title: Member of the Ethics Committee on research involving human beings
Affiliation entity: UPV/EHU
Scope: Evaluate research projects for Ethics committee approval
Type of participation: Board member
Start date (dd/mm/yy): 10/01/2022 End date (dd/mm/yy): Ongoing



Committee title: Member of the Committee for the evaluation of new medicines for primary care

Affiliation entity: UPV/EHU

Scope: Evaluate medicines that have been recently approved for their use in primary care in a public report

Type of participation: Board member

Start date (dd/mm/yy): 11/09/2023

End date (dd/mm/yy): Ongoing